Insight

Diego A. Díaz-García Highlights LIQUIK Study

Diego A. Díaz-García/X

Aug 22, 2025, 10:50

Diego A. Díaz-García Highlights LIQUIK Study

Diego A. Díaz-García, Medical Oncologist, CEO, and Founder of CánCare – Advanced Oncology Specialty, shared a post on X:

“LIQUIK study.
In metastatic NSCLC, LiquidHALLMARK (ctDNA+ctRNA) improved biomarker detection vs ctDNA alone:

+28.6% gene rearrangements
+15.6% actionable biomarkers

Tissue NGS remains gold standard, but ctRNA enhances liquid biopsy yield.”

Title: Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK)

Authors: Jens Samol, David Ng, Jonathan Poh, Min-Han Tan, Richa Dawar, Jennifer Carney, James Orsini Jr, Katherine Scilla, Yew Oo Tan, Tan Min Chin, Chee Keong Toh, Boon Cher Goh, Gilberto Lopes

Read the Full Article.

LIQUIK Study

More posts featuring Diego A. Díaz-García on OncoDaily.

Boon Cher Goh cancer Chee Keong Toh David Ng Diego A. Díaz García Gilberto Lopes James Orsini Jr Jennifer Carney Jens Samol Jonathan Poh Katherine Scilla metastatic NSCLC Min-Han Tan OncoDaily Oncology Richa Dawar Tan Min Chin Yew Oo Tan

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...

World’s Nicest Judge Frank Caprio Dies at 88 After Brave Battle with Pancreatic Cancer

Weight Loss Trial Reports Success for Breast Cancer Patients at One Year Mark

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer